Abstract
Tyrosinemia type I in Japan was reported for the first time in 1957 by Sakai et al. (Jikei Med J 2:1–10, 1957) and Kitagawa et al. (Proc Jpn Acad Ser B 88:192–200, 1957). Five cases of patients with tyrosinemia type I were reported to be definitively diagnosed in Japan. The first case was reported by Sakai et al. and Kitagawa et al. To the best of our knowledge, this was the first definite report in the world. The second and third cases were those of a brother and a sister who underwent liver transplantation and who were the children of a Japanese-descent migrant worker; the fourth case was that of a girl who underwent liver transplantation after 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) treatment, which was reported by Hata et al.; and the fifth case was that of a patient who was administered NTBC, which was reported by Ito et al. These were of the subacute type, wherein residual activity was considerably present. When combined therapy with a low phenylalanine and tyrosine diet and NTBC administration is started after early diagnosis, patients can survive without liver transplantation. Development of liver cancer is not found in the cases in Japan, but performing liver transplantation without delay is necessary when liver cancer is found.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AFP:
-
alpha-fœtoprotein
- ALP:
-
alkaline phosphatase
- APPT:
-
activated partial thromboplastin time
- FAH:
-
fumarylacetoacetate hydrolase
- HPT:
-
heptoplastin T
- γ-GTP:
-
γ-glutamyl transferase
References
Grompe M et al (1995) Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinemia type 1. Nat Genet 10:453–460
Hata I, Shigematsu Y (2012) A case of hypertyrosinemia I. Annual report of the Grant-in-aid for the research on rare and intractable diseases, Health and Labour Sciences Research. (Japanese)
Ito M, Matsuda J, Shinahara H (2005) A case of hypertyrosinemia I with favorable prognosis after administration of long-term NTBC. Bull Spec Formula 41:27–30. (Japanese)
Kelsey G et al (1993) Rescue of mice homozygous for lethal albino deletions: implications for an animal model for the human liver disease tyrosinemia type 1. Genes Dev 7:2285–2297
Lindstedt S et al (1992) Treatment of hereditary tyrosinemia type 1 by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813–817
Michell GA et al (2001) Hypertyrosinemia. In: Scriver CR et al (eds) The metabolic and molecular bases of inherited diseases, 8th edn. McGraw Hill, New York, pp 1777–1805
Nakamura K, Matsumoto S, Mitsubuchi H et al (2015) Diagnosis and treatment of hereditary tyrosinemia in Japan. Pediatr Int 57:37–40
Sakai K, Kitagawa T (1957) An atypical case of tyrosinosis. Part 1. Jikei Med J 2:1–10
Shigematsu K, Hata I (2007) Annual report for the research on rare and intractable diseases. Health Labour Sci Res Grants:86–88
Ueda A, Ito T, Okubo Y et al (2005) A case of hypertyrosinemia I. Bull Spec Formula 41:23–26
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Nakamura, K., Ito, M., Shigematsu, Y., Endo, F. (2017). Tyrosinemia Type I in Japan: A Report of Five Cases. In: Tanguay, R. (eds) Hereditary Tyrosinemia. Advances in Experimental Medicine and Biology, vol 959. Springer, Cham. https://doi.org/10.1007/978-3-319-55780-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-55780-9_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-55779-3
Online ISBN: 978-3-319-55780-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)